Plain-English translation of NCT06836284 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether liraglutide or semaglutide—medications that help reduce weight—work better when combined with a digital tool called Evira. The Evira app helps you track your weight at home and stay connected with your healthcare team, so they can support you throughout your treatment. The study will compare this combined approach to the medication alone.
While this medication has shown real promise in helping teenagers lose weight, many patients regain the weight after stopping treatment. Researchers want to know if adding digital support and monitoring—keeping you engaged and connected to your care team—can help improve long-term results.
You likely qualify if…
You likely don't qualify if…
If you join this study, you'll receive your prescribed obesity medication as usual. Additionally, you'll be given a digital weight scale to use at home each day—it won't display numbers to you, but it will securely send data to an app on your phone. The app shows your weight trends over time and includes a personalized target curve so you can see how you're progressing. You'll also be able to message your healthcare team directly through the app when you need support or have questions. About two-thirds of participants will get this full digital support package, while the other third will continue with standard medication care.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
Sweden